

## **Comorbidities and Tuberculosis Outcomes**

Zelalem Temesgen, MD FIDSA Professor of Medicine Principal Investigator, Mayo Clinic Center for Tuberculosis Editor-in-Chief, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Editor-in-Chief, IDCases

## Disclosures

• No relevant financial relationships


## Learning Objectives

| Describe | how HIV impacts TB outcomes          |
|----------|--------------------------------------|
| Describe | how diabetes impacts TB outcomes     |
| Describe | how malnutrition impacts TB outcomes |
| Describe | how smoking impacts TB outcomes      |
| Describe | how alcohol use impacts TB outcomes  |

## Global estimates of tuberculosis episodes in 2022 attributable to selected risk factors

| Risk factor              | Risk ratio<br>(uncertainty interval) |              | Number of<br>people with the<br>risk factor<br>(millions) | Attributable TB episodes<br>(millions, uncertainty<br>interval) |                |  |
|--------------------------|--------------------------------------|--------------|---|---|----------------|--|
| Alcohol use<br>disorders | 3.3                                  | (2.1 to 5.2) | 297   | 0.73  | (0.52 to 0.99) |  |
| Diabetes                 | 1.5                                  | (1.3 to 1.8) | 509   | 0.37  | (0.27 to 0.48) |  |
| HIV infection            | 14                                   | (12 to 16)   | 39  | 0.89  | (0.73 to 1.1)  |  |
| Smoking                  | 1.6                                  | (1.2 to 2.1) | 998   | 0.70  | (0.50 to 0.95) |  |
| Undernourishment         | 3.2                                  | (3.1 to 3.3) | 711   | 2.2   | (2.0 to 2.4)   |  |


## Impact of Comorbidities on TB Natural History and Outcomes



## Impact of HIV on TB Outcomes

Mayo Clinic Center for Tuberculosis

#### Granuloma formation during MTB infection



Mayo Clinic Center for Tuberculosis

Téllez-Navarrete, Norma A et al. "Malnutrition and tuberculosis: the gap between basic research and clinical trials." Journal of infection in developing countries 15 3 (2021): 310-319 .

|                           | Shariff et al., 20<br>Chan et al., 202<br>Baya et al., 201<br>Desissa et al., 2                     |
|---------------------------|---|
|                           | Sinha et al., 201   |
|                           | van Den Hof et ;<br>Metcalfe et al., 2<br>Lukoye et al., 20<br>Arroyo et al., 20<br>Tesseme et al., |
| Sultana 77 Hagua El       | Mulu et al., 2019<br>Lee et al., 2016<br>Satti et al., 2013   |
| Sultana ZZ, Hoque FU,     | Gunther et al., 2<br>van Halsema et   |
| Beyene J, et al. HIV      | Ulmasova et al.,<br>Minion et al., 20<br>Brito et al., 201  |
| infection and multidrug   | Pavlenko et al.,<br>Salindri et al., 2<br>Chuchottaworn   |
| resistant tuberculosis: a | Fikre et al., 2019<br>Alene et al., 201   |
|                           | Gobena et al., 2<br>Macedo et al., 2<br>Mor et al., 2014  |
| systematic review and     | Sethi et al., 201   |
| meta-analysis. BMC Infect | Gaborit et al., 20<br>Gudo et al., 201  |
|                           | Kusumawati et a<br>Okethwangu et<br>Ershova et al., 2   |
| Dis. 2021;21(1):51.       | Workicho et al.,  |
|                           | Padilla et al., 20  |


| Upper Authors More Tarthity |
|---|
| OR  |

## Trend in tuberculosis treatment success rates by HIV status


|            | Completed<br>n(%) | Cured<br>n(%) | Died<br>n(%) | Failure<br>n(%) | Lost to<br>follow-up<br>n(%) | P-<br>value |
|------------|-------------------|---------------|--------------|-----------------|------------------------------|-------------|
| HIV status |                   |               |              |                 |                              |             |
| Negative   | 1058(47.9)        | 390(17.7)     | 528(23.9)    | 31(1.4)         | 201(9.1)                     |             |
| Positive   | 326(46.6)         | 49(7.0)       | 269(38.5)    | 5(0.7)          | 50(7.2)                      | < 0.001     |

HIV negative status was associated with 22.0% higher proportion of successful treatment outcome compared with being HIV positive

Puplampu P, Kyeremateng I, Asafu-Adjaye O, et al. Evaluation of treatment outcomes among adult patients diagnosed with tuberculosis in Ghana: A 10year retrospective review. IJID Reg. 2023;10:9-14. Published 2023 Nov 10. doi:10.1016/j.ijregi.2023.11.004 Mortality during tuberculosis treatment in South Africa: an 8-year analysis



Cumulative hazard of deaths stratified by type of TB diagnosis with HIV status



Abdullahi, O., Moses, N., Sanga, D. et al. The effect of empirical and laboratoryconfirmed tuberculosis on treatment outcomes. Sci Rep 11, 14854 (2021). https://doi.org/10.1038/s41598-021-94153-0

## Impact of Diabetes on TB Outcomes

Mayo Clinic Center for Tuberculosis

Risk of failure/death for TB patients with DM compared with TB patients without DM

| Study   | Country         | Population<br>with DM<br>Failure and<br>Deaths/<br>Total | Population<br>without DM<br>Failure and<br>Deaths/<br>Total |   | RR (95% CI)      |
|---|-----------------|--|---|---|------------------|
| Ambrosetti, 1995 Report [2  | 3] Italy        | 3/32 (9%)  | 33/737 (4%)   |   | 2.09 (0.68, 6.4) |
| Ambrosetti, 1996 Report [2  | 9] Italy        | 5/50 (10%)   | 20/773 (3%)   |   | 3.87 (1.51, 9.8) |
| Ambrosetti, 1997 Report [3  | 0] Italy        | 2/40 (5%)  | 45/667 (7%)   |   | 0.74 (0.19, 2.9  |
| Centis, 1998 Report [35]  | Italy           | 5/41 (12%)   | 61/1059 (6%)  |   | 2.12 (0.90, 4.9  |
| Centis, 1999 Report [36]  | Italy           | 2/40 (5%)  | 28/852 (3%)   |   | 1.52 (0.38, 6.1  |
| Mboussa, 2003 [47]  | Congo           | 13/32 (41%)  | 13/100 (13%)  |   | 3.13 (1.62, 6.0  |
| Ponce-de-Leon, 2004 [3]   | Mexico          | 42/172 (24%)   | 67/409 (16%)  |   | 1.49 (1.06, 2.1  |
| Anunnatsiri, 2005 [31]  | Thailand        | 4/38 (11%)   | 11/188 (6%)   |   | 1.80 (0.60, 5.3  |
| Singla, 2006 [50]   | Saudi<br>Arabia | 1/187 (<1%)  | 7/505 (1%)  | • | 0.39 (0.05, 3.1  |
| Alisjahbana, 2007 [11]  |                 | 8/94 (9%)  | 32/540 (6%)   |   | 1.44 (0.68, 3.0) |
| Chiang, 2009 [37]   | Taiwan          | 60/241 (25%)   | 161/886 (18%)   |   | 1.37 (1.06, 1.7  |
| Wang, 2009 [56]   | Taiwan          | 13/74 (18%)  | 11/143 (8%)   |   | 2.28 (1.08, 4.8  |
| Summary   |                 |  |   |   | 1.69 (1.36, 2.1  |
| Heterogeneity I-squared = <sup>-</sup><br>Weights are from random e | ,               | sis  |   |   |                  |


Baker, M.A., Harries, A.D., Jeon, C.Y. et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med 9, 81 (2011). https://doi.org/10.1186/1741-7015-9-81

Risk of TB relapse for TB patients with DM compared with TB patients without DM

| Study               | Country         | Population<br>with DM<br>Relapse/<br>Total | Population<br>without DM<br>Relapse/<br>Total |    |            | RR (95% CI)      |
|---------------------|-----------------|--|---|----|------------|------------------|
| Wada, 2000 [54]     | Japan           | 7/61 (11%)                                 | 4/284 (1%)                                    |    |            | 8.15 (2.46, 26.9 |
| Mboussa, 2003 [47]  | Congo           | 6/17 (35%)                                 | 9/77 (12%)                                    |    |            | 3.02 (1.24, 7.35 |
| Singla, 2006 [50]   | Saudi<br>Arabia | 2/130 (2%)                                 | 3/367 (1%)                                    |    |            | 1.88 (0.32, 11.1 |
| Maalej, 2009 [46]   | Tunisia         | 4/55 (7%)                                  | 1/82 (1%)                                     |    | *          | 5.96 (0.68, 51.9 |
| Zhang, 2009 [57]    | China           | 33/165 (20%)                               | 9/170 (5%)                                    |    | _ <u> </u> | 3.78 (1.87, 7.65 |
| Summary             |                 |  |   |    | $\diamond$ | 3.89 (2.43, 6.23 |
| Heterogeneity I-squ | uared = 0%      | (0, 79)                                    |   |    |            |                  |
| Weights are from ra | indom effec     | ts analysis                                |   |    |            |                  |
|                     |                 |  |   | .3 | 1 3.89 15  | і<br>60          |

Baker, M.A., Harries, A.D., Jeon, C.Y. et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med 9, 81 (2011). https://doi.org/10.1186/1741-7015-9-81

Adjusted odds of death for TB patients with DM compared with TB patients without DM.



Baker, M.A., Harries, A.D., Jeon, C.Y. et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med 9, 81 (2011). https://doi.org/10.1186/1741-7015-9-81

| AUTHOR  | 99 age             | 41       | weight   |                |      |      |      | HR [95%CI]      | p value |
|---|--------------------|----------|----------|----------------|------|------|------|-----------------|---------|
| Control g                                       | roup (TB patients) | Exp. Gro | up (TB-D | M patients)    |      |      |      |                 |         |
| Sahakyan et al, 2020                            | 1.88               | 11.11    | 5.21     | 300            | •    |      |      | 0.36[0.23-0.53] | <0.01   |
| Lee et al, 2017                                 | 0.39               | 0.42     | 12.71    |                |      | •    |      | 0.87[0.63-0.97] | <0.01   |
| Siddiqui et al, 2016                            | 1.95               | 5.41     | 6.41 -   |                |      |      |      | 0.28[0.11-0.56] | <0.01   |
| Yoon et al, 2016                                | 0.66               | 5.38     | 11.21    |                |      |      |      | 0.45[0.22-0.71] | <0.01   |
| Delgado-Sánchez et al, 2015                     | 14.5               | 21.2     | 4.3      |                |      |      |      | 0.34[0.14-0.64] | <0.01   |
| HONGGUANG et al, 2015                           | 0.53               | 3.3      | 13.12    |                |      |      |      | 0.29[0.12-0.48] | <0.01   |
| Vijay et al, 2013                               | 0.67               | 4.17     | 5.28     |                |      |      |      | 0.42[0.28-0.69] | <0.01   |
| KV et al, 2013                                  | 3.62               | 4.8      | 7.29     |                |      | -    |      | 0.85[0.72-0.98] | <0.01   |
| Jiménez-Corona et al, 2012                      | 2.24               | 4.68     | 3.19     | 5-3<br>        |      |      |      | 0.53[0.28-0.83] | <0.01   |
| Adane et al, 2023                               | 56.25              | 43.75    | 12.16    | 12 <del></del> |      |      |      | 0.35[0.21-0.59] | <0.01   |
| Chiang et al, 2015                              | 2.47               | 3.37     | 6.36     |                |      |      |      | 0.75[0.44-0.87] | <0.01   |
| Magee et al, 2015                               | 23.58              | 28.13    | 8.76     |                |      |      |      | 0.31[0.14-0.49] | <0.01   |
| Perez-Navarro et al, 2017                       | 22.08              | 19.43    | 4        |                |      |      |      | 0.23[0.17-0.38] | <0.01   |
| hetrogeniety I²= 61%, overall effect<br>p<0.001 | sise z=39.52,      |          | 100      |                | •    |      |      | 0.46[0.27-0.67] | <0.01   |
| 0.  | 01 0.03            | 3        | 0.07     | 0.20           | 0.54 | 1.48 | 4.01 |                 |         |

### Rehman AU, Khattak M, Mushtaq U, et al. The impact of diabetes mellitus on the emergence of multi-drug-resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis. Front Public Health. 2023;11:1244450.

#### Impact of DM on TB treatment failure rates

## Impact of Malnutrition on TB Outcomes

## Malnutrition: Definition

Broadly defined by WHO as deficiencies or excesses in nutrient intake, an imbalance of essential nutrients or impaired nutrient utilization.

A spectrum of nutrition-related states from undernutrition to overweight and obesity.

In practice, malnutrition is often used as a synonym for undernutrition in both academic literature and clinical discourse.

## Malnutrition and Tuberculosis Key Facts

Malnutrition is the leading attributable risk factor for tuberculosis (TB) infection.

The risk of acquiring TB increases by 13.8% for each unit decrease in body mass index (BMI).


Malnutrition is also a risk factor for conversion from latent TB to active disease.


Malnourished TB patients experience poorer treatment outcomes.

Malnourished patients are twice as likely to die from TB compared with non-malnourished patients.

Tuberculosis and malnutrition. World Health Organization 2024


# Relationship between malnutrition, infection and immunity






Mayo Clinic Cente

## Relationship between malnutrition, and Tuberculosis




Bhootra, Y.M., Babu, S. (2018). Malnutrition in Tuberculosis. In: Preedy, V., Patel, V. (eds) Handbook of Famine, Starvation, and Nutrient Deprivation. Springer, Cham. https://doi.org/10.1007/978-3-319-40007-5\_97-1




Tuberculosis Mortality in Amsterdam

DANIELS M. Tuberculosis in Europe during and after the second world war. Br Med J. 1949;2(4636):1065-1072. doi:10.1136/bmj.2.4636.1065



Prevalence of undernutrition (% of population)

**Global Tuberculosis Report 2021** 



Lönnroth, Knut, et al. "A consistent log-linear relationship between tuberculosis incidence and body mass index." International journal of epidemiology 39.1 (2010): 149-155.

## Hazard ratio of the risk of incident TB disease due to undernutrition.

Franco JVA, et al. Undernutrition as a risk factor for tuberculosis disease. Cochrane Database of Systematic Reviews 2024, Issue 6. Art. No.: CD015890. DOI: 10.1002/14651858.CD015890.pub2.


Mayo Clinic Center for Tuberculosis

| Study   |                 | HR<br>with 95% CI    | Country           | ROB1 | ROB2 | ROB3 | ROB4 | ROB5 | ROE |
|---|-----------------|----------------------|-------------------|------|------|------|------|------|-----|
| A: < 10 years   |                 |                      | ,                 |      |      |      |      |      |     |
| Hanrahan 2010 -   | <b>—</b>        | 1.20 [ 0.81, 1.78]   | South Africa      | 0    |      |      |      | 0    |     |
| Chen 2022   |                 |                      | China             |      | ě    | ě    | Õ    | Õ    | ŏ   |
| Li 2013 -   | -               | 1.30 [ 0.92, 1.84]   | Tanzania          | 0    | 0    | Õ    | 0    |      | Ó   |
| Kim 2018  |                 | 1.36 [ 1.15, 1.60]   |                   |      | Õ    | Õ    | Õ    | Õ    | Ő   |
| Aibana 2016   |                 | 1.42 [ 0.74, 2.73]   |                   | Õ    | Õ    | Õ    | Ó    |      | Ĩ   |
| Baker 2012  |                 | 1.60 [ 0.55, 4.68]   |                   |      |      | Õ    | Õ    | 0    |     |
| Choun 2013  |                 | 1.60 [ 1.13, 2.26]   |                   | Õ    | ě    |      | Ó    | Ó    | Ó   |
| Alemu 2020  | -               | 1.91 [ 1.44, 2.53]   |                   | 0    | 0    | •    | 0    | 0    |     |
| Leung 2007  |                 | 2.06 [ 1.46, 2.91]   | China             | 0    |      | •    | •    | 0    |     |
| Park 2022   |                 | 2.21 [ 1.98, 2.46]   |                   |      |      |      | 0    | 0    |     |
| Batista 2013  |                 | 2.25 [ 1.38, 3.67]   | Brazil            | 0    | 0    |      | 0    | 0    | 0   |
| Ganesan 2023  |                 |                      | Subsaharan Africa | 0    | •    | •    | •    | 0    |     |
| Yoo 2021  |                 | 2.36 [ 2.17, 2.57]   |                   | •    | •    | 0    | 0    | 0    |     |
| Getu 2022   |                 | 2.42 [ 1.30, 4.51]   | Ethiopia          | 0    | •    | •    | 0    | 0    | 6   |
| Ahmed 2018  |                 | 2.53 [ 1.27, 5.04]   | Ethiopia          | 0    | 0    | 0    | 0    | 0    | 6   |
| Moore 2007  |                 | 2.80 [ 1.59, 4.93]   | Uganda            | 0    | •    | •    | 0    | 0    | 0   |
| Gedfew 2020   | <b>_</b>        | 2.94 [ 1.23, 7.03]   | Ethiopia          | 0    | 0    |      | 0    | 0    |     |
| Tiruneh 2019  |                 | 3.13 [ 1.77, 5.53]   | Ethiopia          | 0    | 0    |      | 0    | 0    | 6   |
| Maro 2010   |                 | 3.72 [ 1.16, 11.96]  | Tanzania          | 0    | ۲    |      |      | 0    | (   |
| Beshir 2019   |                 | 5.19 [ 1.89, 14.23]  | Ethiopia          | 0    | 0    |      | 0    | •    |     |
| Worodria 2011   |                 | 5.85 [ 1.24, 27.53]  | Uganda            | 0    | 0    |      | 0    | 0    | 0   |
| Gatechompol 2022  |                 | 8.21 [ 2.43, 27.73]  | Thailand          | 0    | •    |      | 0    | 0    |     |
| Heterogeneity: τ² = 0.06, l² = 71.55%, H² = 3.52                | <b></b>         | 2.02 [ 1.74, 2.34]   |                   |      |      |      |      |      |     |
| Test of $\theta_i = \theta_i$ : Q(21) = 70.50, p = 0.00         |                 |                      |                   |      |      |      |      |      |     |
| Test of $\theta = 0$ : z = 9.30, p = 0.00                       |                 |                      |                   |      |      |      |      |      |     |
| B: 10 or more years   |                 |                      |                   |      |      |      |      |      |     |
| Cegielski 2012  |                 | 12.43 [ 5.74, 26.91] | USA               |      | 0    |      | 0    | 0    |     |
| Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$        |                 | 12.43 [ 5.74, 26.91] |                   |      |      |      |      |      |     |
| Test of $\theta_i = \theta_i$ : Q(0) = -0.00, p = .             |                 |                      |                   |      |      |      |      |      |     |
| Test of $\theta = 0$ : $z = 6.39$ , $p = 0.00$                  |                 |                      |                   |      |      |      |      |      |     |
| Overall   | <b>—</b>        | 2.23 [ 1.83, 2.72]   |                   |      |      |      |      |      |     |
| Heterogeneity: $\tau^2 = 0.14$ , $I^2 = 86.16\%$ , $H^2 = 7.22$ |                 |                      |                   |      |      |      |      |      |     |
| Test of $\theta_i = \theta_j$ : Q(22) = 90.92, p = 0.00         | increased rist. |                      |                   |      |      |      |      |      |     |
| Test of $\theta = 0$ : z = 7.91, p = 0.00 reduced risk          | increased risk  |                      |                   |      |      |      |      |      |     |
| Test of group differences: $Q_b(1) = 20.51$ , p = 0.00          |                 | -                    |                   |      |      |      |      |      |     |
|   | 2 4 8 16        |                      |                   |      |      |      |      |      |     |

Sorted by: \_meta\_es 95% prediction intervals

#### Subgroup analysis by HIV status for the risk of incident TB disease due to undernutrition

Franco JVA, et al. Undernutrition as a risk factor for tuberculosis disease. Cochrane Database of Systematic Reviews 2024, Issue 6. Art. No.: CD015890. DOI: 10.1002/14651858.CD015890.pub2.



Sorted by: \_meta\_es

## Nutritional Interventions and TB Outcomes

Increased calorie and protein intake can improve recovery from TB recovery

Nutritional support for TB patients was shown to increase treatment compliance.

Tuberculosis and malnutrition. World Health Organization 2024

## **Nutritional Assessment**

Taking a nutrition-oriented history and examination

Anthropometric assessment such as BMI

**Dietary assessment** 

Laboratory assessment, e.g. albumin, micronutrients (e.g., vitamin D, zinc)

Tuberculosis and malnutrition. World Health Organization 2024

## **Initial Assessment**

#### **Comprehensive Nutritional History**

- Dietary intake,
- Weight history
- Potential barriers to adequate nutrition

Physical Examination: Identify signs of malnutrition


- Muscle wasting
- Edema

## Impact of Smoking on TB Outcomes

Mayo Clinic Center for Tuberculosis

### The impact of cigarette smoking on tuberculosis

- Increased risk of TB infection and active TB disease
- Delay in TB diagnosis
- Increased duration of culture positivity, higher bacillary loads, prolonged smear and culture positivity
- Increased progression of primary tuberculosis
- Increased severity of TB, more extensive pulmonary disease, more lung cavitation, greater need for hospitalization, and more prolonged hospitalization.
- TB treatment failure, recurrence of disease after successful treatment with anti-TB drugs, Treatment interruption, a negative effect on treatment completion, treatment default, treatment loss to follow-up
- Higher mortality
- Increased costs for the patient and the healthcare system.




The effects of cigarette smoke exposure on innate and adaptive immunity that may influence the control of Mycobacterium tuberculosis infection.

## Mechanisms by which cigarette smoke and its nicotine constituent suppress alveolar macrophage anti-mycobacterial activity.

| Impaired Alveolar Macrophage<br>Function | Type of Study  | Mechanism  |                               |
|--|--|--|-------------------------------|
| Antimicrobial activity                   | Alveolar macrophages isolated<br>from the lungs of smokers<br>exposed to cigarette smoke<br>extract in vitro                                   | Attenuation of<br>autophagolysosome formation<br>due to failure of recruitment<br>autophagy adaptors   |                               |
| Antimicrobial activity                   | Isolated lung macrophages from smokers exposed to <i>M. tuberculosis</i> in vitro  | Failure of glycolytic<br>reprogramming associated with<br>decreased expression of genes<br>encoding GLUT-1 as well as<br>glycolysis-mediated activation of<br>the<br>NLRP3 inflammasome-IL-1β-<br>maturation and release pathway |                               |
| Phagocytosis                             | In vitro exposure of a macrophage cell line to cigarette smoke extract   | Decreased expression of the PAMPs, TLR2 and MARCO  |                               |
| Phagocytosis                             | In vitro study using blood<br>monocytes isolated from patients<br>with long-term cigarette<br>smoking-related active<br>tuberculosis           | Upregulated expression of the<br>regulatory miRNA, mi-R-196b-<br>5p, resulting in activation of<br>suppressive STAT3   | Feld                          |
| Antimicrobial activity                   | In vitro study involving smoke-<br>exposed murine macrophages<br>and macrophage cell lines<br>depleted of nAChR or exposed<br>to pure nicotine | Nicotine-mediated defective<br>autophagosome formation due to<br>inhibition of NFkB and activation<br>of Tregs   | a Ris<br>Epid<br>Path<br>13(2 |

Feldman C, et al. Cigarette Smoking as a Risk Factor for Tuberculosis in Adults: Epidemiology and Aspects of Disease Pathogenesis. Pathogens. 2024; 13(2):151.




Effects of cigarette smoke exposure on IFN-y production

Effects of cigarette smoke exposure on MTB bacterial burden and T cell response


Feng Y, et al. Exposure to cigarette smoke inhibits the pulmonary T-cell response to influenza virus and Mycobacterium tuberculosis. Infect Immun. 2011;79(1):229-237. doi:10.1128/IAI.00709-10

## Pooled effect estimate of current smokers and unfavorable treatment outcomes



Wang EY, et al. The impact of smoking on tuberculosis treatment outcomes: a meta-analysis. Int J Tuberc Lung Dis. 2020;24(2):170-175. doi:10.5588/ijtld.19.0002


#### Cumulative hazards for tuberculosis relapse by smoking status



Leung CC, et al. European Respiratory Journal 2015 45(3): 738-745; DOI: https://doi.org/10.1183/09031936.00114214


## Impact of Alcohol Use on TB Outcomes

Estimated tuberculosis incidence rates per 100 000 people attributable to alcohol consumption by countries in 2014




Imtiaz S, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. European Respiratory Journal 2017 50(1): 1700216; DOI: https://doi.org/10.1183/13993003.00216-2017


Estimated tuberculosis mortality rates per 100 000 people attributable to alcohol consumption by countries in 2014




Imtiaz S, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. European Respiratory Journal 2017 50(1): 1700216; DOI: https://doi.org/10.1183/13993003.00216-2017



Wigger GW, et al. The Impact of Alcohol Use Disorder on Tuberculosis: A Review of the Epidemiology and Potential Immunologic Mechanisms. Front Immunol. 2022;13:864817. doi:10.3389/fimmu.2022.864817





| 4                                | Alcoho                | Igroup | Non-alco | hol group |                   |                   |
|----------------------------------|-----------------------|--------|----------|-----------|-------------------|-------------------|
| Author, year                     | Event                 | Total  | Event    | Total     |                   | OR [95% CI]       |
| OS-TB                            |                       |        |          |           |                   |                   |
| Ambrosetti, 1999A                | 7                     | 24     | 107      | 642       | <b>⊢</b>          | 2.06 [0.83, 5.09  |
| Ambrosetti, 1999B                | 7                     | 33     | 108      | 705       |                   | 1.49 [0.63, 3.51  |
| Ambrosetti, 1999C                | 5                     | 38     | 91       | 750       |                   | 1.10 [0.42, 2.88  |
| Bhagat, 2010                     | 17                    | 42     | 7        | 55        | · · · ·           | 4.66 [1.71, 12.73 |
| Bumburidi, 2006*                 | -                     | 762    | -        | 18203     |                   | 3.20 [2.80, 3.70  |
| Centis, 2000                     | 10                    | 35     | 139      | 833       | L                 | 2.00 [0.94, 4.25  |
| Centis, 2002                     | 2                     | 19     | 104      | 764       | · · · · · ·       | 0.75 [0.17, 3.28  |
| Chiang, 2012                     | 36                    | 88     | 74       | 214       | · .               | 1.31 [0.79, 2.18  |
| De Albuquerque, 2007*            | -                     | -      | -        | -         |                   | 1.79 [1.21, 2.66  |
| Diel, 2003                       | 61                    | 127    | 41       | 391       |                   | 7.89 [4.91, 12.69 |
| Ismail, 2013                     | 29                    | 54     | 21       | 113       |                   | 5.08 [2.49, 10.39 |
| Jain, 2016                       | 10                    | 52     | 21       | 189       |                   | 1.90 [0.83, 4.35  |
| Kim, 2007                        | 116                   | 182    | 90       | 166       |                   | 1.48 [0.97, 2.28] |
| Kittikraisak, 2009               | 45                    | 386    | 16       | 168       |                   | 1.25 [0.69, 2.29] |
| Lillebaek, 1999                  | 14                    | 48     | 45       | 227       | , <u> </u>        | 1.67 [0.82, 3.36  |
| Lin, 2015                        | 29                    | 122    | 619      | 2200      |                   | 0.80 [0.52, 1.22  |
| Magee, 2015                      | 16                    | 48     | 10       | 82        |                   | 3.60 [1.47, 8.79  |
| Pimchan, 2012                    | 21                    | 55     | 101      | 340       |                   |                   |
|                                  | -                     | 534    | -        | 1491      |                   | 1.46 [0.81, 2.64  |
| Przybylski, 2014*                | 171                   | 742    | 93       |           | <b>—</b> —        | 1.74 [1.29, 2.36  |
| Ramachandran, 2017               |                       |        | 93       | 1170      |                   | 3.47 [2.64, 4.55  |
| Santha, 2002                     | 55                    | 146    |          | 435       |                   | 2.42 [1.61, 3.64  |
| Siemion-Szczesniak, 2012A        | 37                    | 73     | 45       | 232       |                   | 4.27 [2.43, 7.50  |
| Siemion-Szczesniak, 2012B        | 24                    | 61     | 56       | 200       | HH                | 1.67 [0.92, 3.04  |
| Tabarsi, 2012                    | 18                    | 53     | 23       | 58        |                   | 0.78 [0.36, 1.70  |
| Volkmann, 2014                   | 2569                  | 27145  | 12488    | 155897    |                   | 1.20 [1.15, 1.26] |
| Random-effects model (P < 0.001; | I <sup>2</sup> = 93%) |        |          |           | <b>•</b>          | 1.99 [1.57, 2.51] |
| /IDR-TB                          |                       |        |          |           |                   |                   |
| Aibana, 2017                     | 56                    | 67     | 227      | 281       | <b>⊢</b> ∔•—-1    | 1.21 [0.59, 2.47] |
| Cox, 2007                        | 10                    | 20     | 23       | 67        | <b>⊢</b>          | 1.91 [0.70, 5.26  |
| De Albuquerque, 2001             | 42                    | 151    | 19       | 135       |                   | 2.35 [1.29, 4.29  |
| Gadallah, 2016                   | 11                    | 21     | 59       | 207       |                   | 2.76 [1.11, 6.84  |
| Gegia, 2012                      | 51                    | 94     | 128      | 286       | <u> </u>          | 1.46 [0.92, 2.34  |
| Gegia, 2015                      | 20                    | 104    | 29       | 175       |                   | 1.20 [0.64, 2.25  |
| Jain, 2014                       | 22                    | 27     | 50       | 103       |                   | 4.66 [1.64, 13.26 |
| Jeong, 2015                      | 6                     | 33     | 59       | 304       |                   | 0.92 [0.36, 2.34  |
| Kendall, 2013                    | 74                    | 131    | 29       | 78        |                   | 2.19 [1.23, 3.90  |
| Kuksa, 2014                      | 36                    | 64     | 27       | 68        |                   | 1.95 [0.98, 3.90  |
|                                  | 207                   | 489    | 121      | 478       |                   |                   |
| Kurbatova, 2012<br>Leimane, 2010 | 122                   | 479    | 62       | 478       |                   | 2.17 [1.65, 2.85  |
|                                  |                       |        |          |           |                   | 1.87 [1.33, 2.63  |
| Magee, 2014                      | 57                    | 86     | 451      | 967       |                   | 2.25 [1.41, 3.58  |
| Miller, 2012                     | 126                   | 253    | 34       | 154       |                   | 3.50 [2.22, 5.51  |
| Oliveira, 2013                   | 22                    | 61     | 63       | 196       |                   | 1.19 [0.65, 2.18  |
| Prajapati, 2017                  | 19                    | 20     | 60       | 88        | ► ► ►             | 8.87 [1.13, 69.59 |
| Scuffell, 2017                   | 6                     | 8      | 31       | 41        |                   | 0.97 [0.17, 5.58  |
| Velasquez, 2016                  | 66                    | 122    | 481      | 1424      |                   | 2.31 [1.59, 3.35  |
| Random-effects model (P < 0.001; | /² = 32%)             |        |          |           | •                 | 2.00 [1.73, 2.32  |
| * Counts unavailable             |                       |        |          |           |                   |                   |
|                                  |                       |        |          |           | 0.15 0.5 1 2 5 15 |                   |

OR

#### Meta-analysis results for poor treatment outcomes

| Treatment outcome           | Studies<br><i>n</i> | Summary effect<br>estimate | 95% CI    |
|-----------------------------|---------------------|----------------------------|-----------|
| Poor outcome A*             | 25                  | 1.99                       | 1.57–2.51 |
| Poor outcome B <sup>+</sup> | 12                  | 2.55                       | 1.77–3.66 |
| Death                       | 22                  | 1.58                       | 1.24–2.00 |
| Treatment failure           | 13                  | 3.12                       | 1.83–5.33 |
| LTFU                        | 29                  | 2.25                       | 1.74–2.91 |

B) Meta-analysis results for poor treatment outcomes, studies on mu

| Treatment outcome  | Studies<br><i>n</i> | Summary effect<br>estimate           | 95% CI  |
|--|---------------------|--------------------------------------|---|
| Poor outcome A*<br>Poor outcome B <sup>+</sup><br>Death<br>Treatment failure | 18<br>10<br>6<br>4  | 2.00<br>1.47<br>1.38<br>1.54<br>1.87 | 1.73–2.32<br>1.06–2.05<br>1.04–1.83<br>1.09–2.17<br>1.56–2.24 |

Ragan EJ, et al. The Impact of Alcohol Use on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. Int J Tuberc Lung Dis (2020) 24(1):73–82. doi: 10.5588/ijtld.19.0080

## **Tuberculosis and Comorbidities**



Several medical conditions are risk factors for TB and for poor TB treatment results.



Identifying these conditions in people diagnosed with TB and providing the appropriate interventions will improve the outcomes of both these conditions and TB



Many of these conditions are highly prevalent in the general population.



Reducing the prevalence of these conditions can help prevent TB.



### Thank you